ABSTRACT Two cycloheximide-resistant mutants of Tetrahymena thermophila were analyzed to determine the site of their cycloheximide resistance. The mutations in both strains had been previously shown to be genetically dominant and located at separate loci (denoted Chx-A and Chx-B). Strains carrying these mutations were readily distinguished by the extent to which they were resistant to the drug. The homozygous double mutant was more resistant than either single mutant. Cell-free extracts of wild type and of the three mutant strains, assayed for protein synthetic activity by both runoff of natural mRNA and poly(U)dependent phenylalanine polymerization, demonstrated that in vitro the mutants were arlmore resistant than the wild type. Further fractionation of the cell-free systems into ribosomes and su ernates localized cycloheximide resistance to the ribosome for both Chx-A and Chx-B homozygotes. Ribosome dissociation and pairwise subunit mixing in the in vitro system indicated that ribosome resistance was conferred by the 60S subunit from one strain whereas resistance in the other strain was mediated through the 40S subunit. This was further confirmed by reconstruction of all four cycloheximide-resistance "phenotypes" by mixing ribosomal subunits from appropriate strains. This finding suggests that the mechanisms by which these mutations confer resistance to cycloheximide are different.
Cycloheximide is an antibiotic that inhibits translation on eukaryotic cytoplasmic ribosomes. The primary site of inhibition has been reported as initiation (1, 2) , elongation (3) (4) (5) , and termination (6, 7) . Oleinick (8) has recently shown that all energy-dependent steps in translation are sensitive to the drug; the relative effect of the drug on the different translation steps appears to vary depending on the cycloheximide concentration. Similar concentration-dependent inhibition has been demonstrated in yeast (9) . It has been suggested (7) that cycloheximide may interfere with GTP binding or hydrolysis at each of these steps, but this has yet to be shown. Rao and Grollman (10) demonstrated that the cycloheximide resistance of Saccharomycesfragilis (which is naturally resistant to the drug) could be localized to the large subunit of the ribosome. This was accomplished by mixing ribosomal subunits of S. fragilis and S. cerevislae (which is sensitive to cycloheximide) and showing that the in vitro resistance of the reconstituted ribosomes required the S. fragilis 60S subunit. The interpretation of this result by other investigators was that cycloheximide resistance or sensitivity was a property of the 60S subunit, presumably because cycloheximide bound there (11) . Direct evidence of cycloheximide binding is lacking but the results of Skogerson and Wakatama (12) and Somasunduran and Skogerson (13) with yeast ribosomes are consistent with this interpretation.
Mutations altering cycloheximide sensitivity of ribosomes have been described in yeast (14) (15) (16) , Neurospora (17) , Physarum (18) , and Chinese hamster ovary cell lines (19) . Jimenez et al. (15) demonstrated that the cycloheximide resistance of one of their mutants was attributable to an altered 60S subunit, and it was further reported that two-dimensional gel electrophoresis of this subunit revealed an altered protein. However, in a discussion of this mutation, cgh2, McLaughlin (16) indicated that the molecular alteration of the 60S subunit is unknown. In this paper we describe the preliminary characterization of two different cycloheximide-resistant mutants of Tetrahymena thermophila. We show that both mutations confer different degrees of resistance to the ribosome and that the resistance of one mutant is large subunit-associated and that of the other is small subunit-associated. The mechanisms by which these two mutations might confer resistance to cycloheximide are discussed.
EXPERIMENTAL PROCEDURES Strains, Media, and Culture Conditions. The mutant strains CU333, CU334, and CU335 (Cornell University stock designations) were homozygotes, derived from T. thermophila inbred strain B. Selection of the Chx-B mutation and construction of strains will be described elsewhere (M. Ares and P. Bruns). The wild-type strain used was B1868, mating type IV. For labeling of growing cells, cultures were grown at 300 in 1% Proteose peptone (Difco)/0.003% Na4EDTA (Geigy). Cell-free extracts were prepared from cultures grown at 30°in 1% Proteose peptone/0.25% yeast extract/0.003% Na4EDTA, to increase the span of exponential growth.
In formed an in vivo dose-response study with exponentially growing cells. Fig. 1 shows the results of one such experiment. Although there was not a perfect correspondence between minimum lethal dose and maximal inhibition of incorporation in vivo, the results are in relative agreement. In both instances, CU335 was about 20 times more resistant than CU334 and about 1.5 times more resistant than CU333.
In Vitro Cycloheximide Sensitivity. As an assay for protein synthesis in vitro, poly(U)-directed poly(Phe) synthesis was measured in cell-free extracts with varying concentrations of cycloheximide. By this assay we found (Fig. 2 ) that all three mutant strains were more resistant to cycloheximide inhibition than was the wild type. Furthermore, CU335 extracts were more resistant than either CUM or CU334 extracts. Although the orders of magnitude of in vitro resistance were not the same as the in vvo resistances (discussed below) the results were reproducible (three experiments) and suggested that decreased uptake was not the cause of resistance.
To identify the resistant cell component we fractionated the crude extract. Ribosomes were pelleted from each of the cellfree extracts, and cycloheximide sensitivity of wild-type ribosomes was tested in each of the four ribosome-free supernates. In addition, ribosomes from the four strains were assayed for cycloheximide resistance in wild-type supernate. These mixing experiments should (i) confirm the cytoplasmic location of the resistance and (ii) localize the resistance of the extracts to either the ribosome fraction or to the postribosomal supernate. When wild-type ribosomes were tested in the four ribosome-free extracts, all four combinations showed equivalent dose responses (Fig. 3 left) . However, the reciprocal mixing experiment demonstrated that the resistance seen in the crude cell-free extracts (Fig. 3 right) could be generated by ribosomes from the three mutant strains. Comparison of Figs. 2 and 3 right shows that the dose-response curves are nearly superimposable; thus, both quantitatively and qualitatively, the ribosomes possess the cycloheximide resistance demonstrable in the poly(U) system.
Validity of the Assay System. Whereas the in vivo cycloheximide responses of the four strains were maximally separated by two orders of magnitude of cycloheximide concentration (Fig. 1) , the maximal resistance in vitro was found only at 10 times the concentration of cycloheximide necessary to inhibit wild-type extracts (Figs. 2 and 3 right) . However, a poly(U) system cannot assay effects on any step in protein synthesis except elongation (23, 24) . The measurement of in vivo inhibition is the result of inhibition of all steps in protein synthesis. If elongation in wild-type cells is less sensitive to cycloheximide than is either initiation or termination, as has been shown in Chinese hamster ovary cells (8) , then the in vitro results need not agree quantitatively with the in vivo measurements. Furthermore, the poly(U)-directed poly(Phe) incorporations are not carried out under optimal conditions for natural mRNA translation.
To assay the inhibition of elongation under more "natural" conditions, we measured inhibition of incorporation in a cellfree polyribosome runoff system. With this system as our estimate of inhibition of elongation, the mutant extracts were more resistant than the wild-type extract (Fig. 4) . The resistance of CU335 was 10 times greater than that of the wild type; the values of CU333 and CU334 again fell betweefi'those for the wild type and the double mutant (results not shown). The actual levels of resistance in the runoff system were approximately 5 times greater than in the poly(U) system. Although natural initiation does not occur in the latter system (24), the ribosomes must attach to the poly(U) in some manner that may be sensitive to cycloheximide. This could affect the absolute levels of resistance. However, because the relative differences were the same, we concluded that both in vitro systems measured similar or identical steps of protein synthesis. Even though we cannot account for the relative differences seen when comparing the in vitro and in vivo dose responses, our data show that the ribosomes from the four strains differ in their cycloheximide sensitivity at least one step in the protein synthetic pathway.
Ribosomal Subunit Localization of Resistance. Further analysis of the mutants was done with the poly(U) assay system to determine which ribosomal subunit was required to confer cycloheximide resistance to the ribosome. Ribosomes from CU333, CU334, CU335, and wild-type extracts were dissociated and reassociated in all pairwise combinations and tested for activity at 10 AM cycloheximide, a concentration that should discriminate among all possible ribosomal phenotypes (see Fig.   2 ). Tables 2-4 give the results of several experiments. First, cycloheximide resistances of homologous reassociations were compared to the resistance of the undissociated ribosomes from which they were derived. Table 2 indicates that (i) dissociation and reassociation does not cause a large loss in overall protein synthetic activity of the ribosome and (ii) the in vitro cycloheximide resistance is retained (in fact it is slightly enhanced). Thus, at 10 .tM cycloheximide, the four "phenotypes" are readily distinguishable from one another. The cycloheximide sensitivity of hybrid ribosomes composed of one wild-type and one mutant subunit clearly suggested ( Table 3) tant-wild-type subunit combinations and that phenotypically double mutant and wild-type ribosomes may be formed by using CU333 and CU334 subunit combinations.
These hybrid combinations, their predicted levels of resistance, and the actual resistances found are shown in Table 4 . Except for the third combination set (CU334 + CU335 subunits), which gave higher resistances than predicted (although relative resistances are still consistent), there is good agreement between actual and predicted resistances. We conclude that CU334 resistance in vitro requires the CU334 40S subunit, CU333 ribosomal resistance is conferred by its 60S subunit; and CU335 in vitro resistance is due to combined effects of the two subunits.
DISCUSSION
Two cycloheximide-resistance mutants of T. thermfophila have been shown to have resistant ribosomes in vitro. Resistance of CU333 ribosomes requires the presence of the 60S subunit.
Given the current information on the probable cycloheximide binding site (or sites) (12, 13) and the ribosomal subunit location of other cycloheximide-resistant mutants (10, 15) (25) . Assuming that the CU334 40S ribosomal subunit is changed in structure, one can imagine that the affinity of cycloheximide for the ribosome is also different. This could occur either by changing the conformation of the entire ribosome or by masking the cycloheximide binding site or both.
Is the in vio resistance of the two strains due entirely to the demonstrated in vitro ribosomal resistance? Genetically, each mutant behaves as if it were the result of a mutation at a single locus; typical Mendelian ratios are found in crosses with these strains (unpublished data). Although pleiotropic mutations that affect ribosomal resistance to antibiotics and other physiological functions at the cell membrane exist in bacteria (26) , they are uncommon. It seems unlikely that we have pleiotropic mutations like the above. However, until cycloheximide uptake and internal concentration can be measured in our strains we cannot rule out the possibility of the exsistence of closely linked mutations that alter cycloheximide transport (or toxicity) in intact cells.
However, assuming that the ribosomal resistance detected Prior to these experiments, the Chx-A locus was considered to be an unlikely candidate for a ribosomal function because mutations at the locus are dominant. Ribosomal drug resistance in prokaryotes is recessive (27) . Recessive ribosomal drug resistance has also been shown for Chinese hamster ovary cell lines (28) and for yeast (29) . Interestingly, the cycloheximide-resistant ribosomal mutations described in yeast (15) , Neurospora (17) , and Physarum (18) do not behave as true recessives, either in yeast diploids or in heterokaryons of Neurospora and of Physarum. A trivial explanation for semidominance in the latter (n = 1) * As in Table 2 Table 2 for reassociated subunits in 10,uM cycloheximide was taken as the "phenotype" expected-+ = 22%; CU334 = 36%; CU3M3 = 48%; CU335 = 69%.
two organisms involves unequal nuclear ratios. However, a possible explanation for the semidominance of cycloheximide resistance may be the site of action of the drug. If inhibition occurs prior to the formation of the mRNA-ribosome initiation complex, then sensitive ribosomes will be selectively excluded from polyribosomes. Thus, resistant ribosomes will preferentially translate mRNA, and heterozygotes will still have functioning protein synthetic machinery. However, until ribosomal cycloheximide-resistant mutants that have clear alterations in ribosomal structural proteins are found, this hypothesis cannot be tested.
